TriangleDecipHER (NCT05504707)
DecipHER trial for Triple Negative Breast Cancer (NCT05504707). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for early-stage breast cancer that is triple negative or has low estrogen receptor levels.
The idea: train immune cells outside the body, then inject them into the tumor. Dendritic cells, which present targets to other immune cells, are primed with two proteins, HER2 and HER3. Participants receive eight ultrasound-guided injections into the tumor, twice a week, alongside standard chemotherapy given before surgery.
The study raises the dose in three steps to find the highest dose with acceptable side effects. At Moffitt Cancer Center in Tampa, Ricardo Costa leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.